Skip to main content
Premium Trial:

Request an Annual Quote

Isogen to Distribute Mobidiag's Amplidiag MDx Products

NEW YORK (GenomeWeb) – Finnish molecular diagnostics firm Mobidiag announced today that it has signed a deal making Isogen Life Sciences the exclusive distributor of all its Amplidiag in vitro diagnostic products in Belgium, the Netherlands, Luxembourg, and Spain.

The Amplidiag line includes PCR-based tests for various gastrointestinal infections including two CE-IVD marked assays — Bacterial GE, which detects Campylobacter, Salmonella, Shigella, Yersinia, and five different Escherichia coli pathotypes; and Amplidiag C. difficile+27 for identifying toxin-producing Clostridium difficile — as well as the Amplidiag Easy automated platform that runs the tests. The firm also sells Amplidiag tests for H. pylori, stool parasites, and CarbaR+VRE, which identifies five major and clinically most relevant carbapenemase groups and two vancomycin resistance markers.

"Since Mobidiag's inception, we have been focusing our activity towards [the] Nordic region and France mainly," Mobidiag CEO Tuomas Tenkanen said in a statement. "We are now in a phase of great expansion and extending our European coverage with the support of reliable partners." 

Last year, the company inked a deal giving Unilabs the right to market the Amplidiag products in Sweden and Norway. Tenkanen told GenomeWeb about a year ago that Mobidiag aims to bring its tests to the US market in 2017.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.